Peritoneal Dialysis Market Report by Treatment Type (Continuous Ambulatory Peritoneal Dialysis, Automated Peritoneal Dialysis ), Product, End User, and Region 2025-2033
º¹¸·Åõ¼® ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 180¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 265¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.16%¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â ¿äÀÎÀº Àü ¼¼°è Åõ¼® ¼¾ÅÍ ¼ö Áõ°¡, ½ÅÀå Áúȯ °ü¸®¸¦ ÃËÁøÇÏ´Â Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡, Áö¼ÓÀû ¿Ü·¡ Åõ¼®(CAPD) äÅà Ȯ´ë, ½ÅÈï±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë µîÀÔ´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ °¡Àå Å« º¹¸·Åõ¼® ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÀÌ´Â À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ³ëÀÎ Àα¸ÀÇ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
º¹¸·Åõ¼®(PD)Àº ½ÅºÎÀü Ä¡·á¹ýÀÇ ÀÏÁ¾À¸·Î, ¼ö¼úÀ» ÅëÇØ º¹° ³» ¶Ç´Â º¹ºÎ¿¡ ºÎµå·¯¿î ÇÃ¶ó½ºÆ½ Æ©ºê³ª Ä«Å×Å͸¦ »ðÀÔÇÏ´Â ¹æ¹ýÀÔ´Ï´Ù. Ä«Å×ÅͰ¡ »ðÀԵǸé Ä«Å×ÅÍ °üÀ» ÅëÇØ ¹«±Õ ¼¼Á¤¾×ÀÌ ÁÖÀԵǾî ü³» ³ëÆó¹°À» Á¦°ÅÇϰí Ç÷¾×À» °É·¯³À´Ï´Ù. ÀÏÁ¤ ½Ã°£ÀÌ Áö³ª¸é ¾×ü¿Í ¿©°úµÈ ºÒÇÊ¿äÇÑ ¼ººÐÀº º¹ºÎ¿¡¼ Èê·¯³ª¿Í Æó±âµÇ¸ç, PD´Â Áö¼ÓÀû ¿Ü·¡ ¿ä¹ý(º¹¸·Åõ¼®)°ú Áö¼ÓÀû ¼øÈ¯ ¿ä¹ý(CCPD)À¸·Î ±¸ºÐµË´Ï´Ù. ÀÌ µÎ °¡Áö ¹æ¹ýÀº Ä¡·áÀÇ À¯¿¬¼ºÀ» Á¦°øÇϰí Åõ¼® ¼¾Å͸¦ ¹æ¹®ÇØ¾ß ÇÒ Çʿ伺À» ÁÙ¿©ÁÖ¸ç, ´õ ³ªÀº ÀÓ»ó °á°ú¸¦ °¡Á®¿À°í, ±× °á°ú Åõ¾à·®°ú ½ÄÀÌ Á¦ÇÑÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î PD´Â Áý¿¡¼ ÇÒ ¼ö ÀÖ°í ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê±â ¶§¹®¿¡ º´¿ø°ú ÀÇ·á ¼¾ÅÍ¿¡¼ ½ÅºÎÀü Ä¡·á¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
º¹¸·Åõ¼® ½ÃÀå µ¿Çâ:
¸»±â ½ÅºÎÀüÁõ(ESRD) À¯º´·ü Áõ°¡
¸»±â ½ÅºÎÀüÁõ(ESRD)ÀÇ À¯º´·ü Áõ°¡´Â º¹¸·Åõ¼® ¼¼°è ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î, ESRD ȯÀÚÀÇ »ýÁ¸À» À§Çؼ´Â Åõ¼®À̳ª ½ÅÀåÀ̽ÄÀÌ ÇÊ¿äÇѵ¥, º¹¸·Åõ¼®Àº ÆíÀǼº°ú °¡Á¤ ³» Ä¡·áÀÇ Æ¯¼ºÀ¸·Î ÀÎÇØ ¼±È£µÇ´Â Ä¡·á¹ýÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÅÀå µ¥ÀÌÅÍ ½Ã½ºÅÛ¿¡ µû¸£¸é 2015³â ESRD ½Å±Ô Áø´Ü °Ç¼ö´Â 124,411°ÇÀ¸·Î ¸Å³â ¾à 2¸¸ °Ç¾¿ Áõ°¡Çϰí ÀÖÀ¸¸ç, Àü ¼¼°èÀûÀ¸·Î ESRD ȯÀÚ ¼ö°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó º¹¸·Åõ¼®À» Æ÷ÇÔÇÑ È¿°úÀûÀ̰í Á¢±ÙÇϱ⠽¬¿î Åõ¼® ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Åõ¼® ±â¼úÀÇ ¹ßÀüÀ¸·Î ´õ¿í °¡¼Óȵǰí ÀÖÀ¸¸ç, ESRD ȯÀÚµéÀÇ Áõ°¡ÇÏ´Â ÀÇ·á ¼ö¿ä¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù.
´ç´¢º´°ú °íÇ÷¾Ð Áõ°¡
´ç´¢º´°ú °íÇ÷¾ÐÀÇ Áõ°¡´Â ¸¸¼º ½ÅÀå Áúȯ(CKD)°ú ¸»±â ½ÅÀå Áúȯ(ESRD)ÀÇ ÁÖ¿ä ¿øÀÎÀ̱⠶§¹®¿¡ º¹¸·Åõ¼® ½ÃÀå Á¡À¯À² È®´ë¿¡ ±â¿©ÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ´ç´¢º´°ú °íÇ÷¾ÐÀº ¸ðµÎ Ç÷°üÀ» ¼Õ»ó½ÃŰ°í ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ½ÅÀå ±â´ÉÀ» ÀúÇϽÃÄÑ °á±¹ »ýÁ¸À» À§ÇØ Åõ¼®À̳ª ½ÅÀå À̽ÄÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´°ú °íÇ÷¾ÐÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ƯÈ÷ °í·ÉÈ »çȸ¿¡¼ ½ÅºÎÀüÁõ »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó º¹¸·Åõ¼®À» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Åõ¼® Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â º¹¸·Åõ¼® ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. º¹¸·Åõ¼®Àº ȯÀÚ¿¡°Ô Æí¸®ÇÑ ÀçÅà ¼Ö·ç¼ÇÀ» Á¦°øÇϱ⠶§¹®¿¡ ÀÌ·¯ÇÑ ÀϹÝÀûÀÎ °Ç° »óÅÂ¿Í °ü·ÃµÈ ½ÅºÎÀüÁõ °ü¸®¿¡ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.
ÀÇ·áºñ ÁöÃâ Áõ°¡
ÀÇ·áºñ ÁöÃâ Áõ°¡´Â °í±Þ Åõ¼® Ä¡·á¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÏ´Â µ¿½Ã¿¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¼±Áø±¹À» Áß½ÉÀ¸·Î Àü ¼¼°èÀûÀ¸·Î ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÅºÎÀü°ú °°Àº ¸¸¼ºÁúȯ °ü¸®¿¡ ´õ ¸¹Àº ÀÚ±ÝÀÌ ÇÒ´çµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ÀÎÇÁ¶ó °³¼±, ´õ ³ªÀº ±³À°À» ¹ÞÀº ÀÇ·áÁø, ÃÖ÷´Ü º¹¸·Åõ¼® ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¹¸·Åõ¼® ½ÃÀå ºÐ¼® º¸°í¼¿¡ µû¸£¸é, ÀÇ·á ¿¹»êÀÇ Áõ°¡·Î ÀÎÇØ ¼¾ÅÍ ³» Ç÷¾×Åõ¼®¿¡ ºñÇØ ºñ¿ë È¿À²ÀûÀÌ°í Æí¸®ÇÑ ÀçÅà ġ·áÀÇ µµÀÔÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àå±âÀûÀÎ Åõ¼® ÀǷḦ Áö¿øÇÏ´Â Á¤ºÎ ÇÁ·Î±×·¥ ¹× º¸Çè Á¤Ã¥µµ ¼¼°è °¢±¹¿¡¼ ¸¶·ÃµÇ°í ÀÖ¾î ȯÀÚÀÇ °æÁ¦Àû ºÎ´ãÀ» ÁÙÀ̰í Á¾ÇÕÀûÀÎ ÀÇ·á ½Ã½ºÅÛÀÇ ÀϺημ Á¢±Ù¼ºÀÌ ÁÁ°í ǰÁúÀÌ ¿ì¼öÇÑ º¹¸·Åõ¼® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»ç ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼Ò°³
Á¦5Àå ¼¼°èÀÇ º¹¸·Åõ¼® ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª : Ä¡·á À¯Çüº°
- Áö¼Ó º¸Çà º¹¸·Åõ¼®(CAPD)
- ÀÚµ¿ º¹¸·Åõ¼®(APD)
Á¦7Àå ½ÃÀå ³»¿ª : Á¦Ç°º°
- º¹¸·Åõ¼® ¼Ö·ç¼Ç
- º¹¸·Åõ¼® µð¹ÙÀ̽º
- º¹¸·Åõ¼® ¼¼Æ®
- º¹¸·Åõ¼® Ä«Å×ÅÍ
- ±âŸ
Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°
- ÀçÅà Åõ¼®
- Åõ¼® ¼¾ÅÍ¿Í º´¿ø ±â¹Ý Åõ¼®
Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå SWOT ºÐ¼®
Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦12Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀï Á¤µµ
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦13Àå °¡°Ý ºÐ¼®
Á¦14Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ °³¿ä
- Amecath
- Baxter International Inc.
- Fresenius Medical Care AG & Co. KGaA
- Medical Components Inc.
- Medionics International Inc.
- Medtronic plc
- Merit Medical Systems Inc.
- Mitra Industries Pvt. Ltd.
- Newsol Technologies Inc.
- Nipro Canada(Nipro Medical Corporation)
- Poly Medicure Limited
- Terumo Corporation
- Utah Medical Products Inc.
ksm
The global peritoneal dialysis market size reached USD 18.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 26.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.16% during 2025-2033. The market is being driven by the rising number of dialysis centers worldwide, the increasing government initiatives to promote kidney disease management, the growing adoption of continuous ambulatory peritoneal dialysis (CAPD), and the expanding healthcare infrastructure in developing countries. At present, North America holds the largest peritoneal dialysis market share, driven by favorable reimbursement policies and the rising geriatric population.
Peritoneal dialysis (PD) represents a type of kidney failure treatment procedure wherein a soft plastic tube or catheter is placed in the abdominal lining or belly through surgery. Once it is positioned, a sterile cleansing fluid is transmitted by the duct that helps filter the blood inside an individual's body by removing waste products. After a period of time, the liquid and filtered unwanted components flow out of the abdomen and are discarded. PD is differentiated into continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis (CCPD). These approaches offer treatment flexibility, reduce the need to visit dialysis centers, and provide better clinical outcomes, resulting in lesser medications and fewer food restrictions. Apart from this, it can be carried out at home and is needle-free; thus, PD is used by hospitals and healthcare centers to treat kidney failures.
Peritoneal Dialysis Market Trends:
Growing prevalence of end-stage renal disease (ESRD)
The growing prevalence of end-stage renal disease (ESRD) is a key factor driving the global peritoneal dialysis market growth as ESRD patients require dialysis or kidney transplantation to survive, with peritoneal dialysis emerging as a preferred treatment due to its convenience and home-based nature. According to the United States Renal Data System, there were 124,411 new ESRD diagnoses in 2015, with the disease increasing at about 20,000 cases per year. As the number of ESRD cases continues to rise globally, the demand for effective and accessible dialysis options, including peritoneal dialysis, increases. This trend is further supported by advancements in dialysis technologies, helping to meet the growing healthcare needs of the expanding ESRD population.
Increasing incidences of diabetes and hypertension
The rising incidences of diabetes and hypertension are significant drivers contributing to the augmenting peritoneal dialysis market share, as these conditions are the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Both diabetes and hypertension damage blood vessels and reduce kidney function over time, ultimately requiring dialysis or kidney transplantation for survival. With the global prevalence of diabetes and hypertension on the rise, particularly in aging population, there has been a corresponding increase in kidney failure cases. As a result, the demand for various dialysis treatments, including peritoneal dialysis, is escalating, thereby impelling the peritoneal dialysis market growth. This type of dialysis offers a convenient, home-based solution for patients, making it a preferred choice for managing kidney failure linked to these common health conditions.
Rising healthcare expenditures
Rising healthcare expenditures are also driving the market while enabling broader access to advanced dialysis treatments. As healthcare spending increases globally, especially in developed countries, more funds are allocated to managing chronic diseases like kidney failure. This allows for improved infrastructure, better-trained medical professionals, and access to cutting-edge peritoneal dialysis technologies. Additionally, according to the peritoneal dialysis market analysis report, increased healthcare budgets facilitate the adoption of home-based treatments, which can be more cost-effective and convenient compared to in-center hemodialysis. Government programs and insurance policies are also better positioned across numerous countries across the globe to support long-term dialysis care, thus easing the financial burden on patients and driving the demand for accessible, quality peritoneal dialysis solutions as part of comprehensive healthcare systems.
Peritoneal Dialysis Market Segmentation:
Breakup by Treatment Type:
- Continuous Ambulatory Peritoneal Dialysis (CAPD)
- Automated Peritoneal Dialysis (APD)
Breakup by Product:
- Peritoneal Dialysis Solution
- Peritoneal Dialysis Devices
- Peritoneal Dialysis Sets
- Peritoneal Dialysis Catheters
- Others
Breakup by End User:
- Home-based Dialysis
- Dialysis Centers and Hospital-based Dialysis
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global peritoneal dialysis market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
- Amecath
- Baxter International Inc.
- Fresenius Medical Care AG & Co. KGaA
- Medical Components Inc.
- Medionics International Inc.
- Medtronic plc
- Merit Medical Systems Inc.
- Mitra Industries Pvt. Ltd.
- Newsol Technologies Inc.
- Nipro Canada (Nipro Medical Corporation)
- Poly Medicure Limited
- Terumo Corporation
- Utah Medical Products Inc.
Key Questions Answered in This Report:
- How has the global peritoneal dialysis market performed so far, and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global peritoneal dialysis market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global peritoneal dialysis market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Peritoneal Dialysis Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Continuous Ambulatory Peritoneal Dialysis (CAPD)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Automated Peritoneal Dialysis (APD)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Product
- 7.1 Peritoneal Dialysis Solution
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Peritoneal Dialysis Devices
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Peritoneal Dialysis Sets
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Peritoneal Dialysis Catheters
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End User
- 8.1 Home-based Dialysis
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Dialysis Centers and Hospital-based Dialysis
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Amecath
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Baxter International Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Fresenius Medical Care AG & Co. KGaA
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Medical Components Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Medionics International Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Medtronic plc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Merit Medical Systems Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Mitra Industries Pvt. Ltd.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Newsol Technologies Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 Nipro Canada (Nipro Medical Corporation)
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.11 Poly Medicure Limited
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Terumo Corporation
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.13 Utah Medical Products Inc.
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio
- 14.3.13.3 Financials